AKT1 and neoplasm: demonstrated that low-dose high-density DTX (11 mg/kg) or PTX (11 mg/kg) indirectly activated the killing effect of T cells on tumor cells by activating the PI3K/AKT/NF-κB signaling pathway, promoting the exposure of antigen on the surface of the tumor cells, and further activating the antigen-presenting function of antigen-presenting cells.